AbbVie Inc. (ABBV) Financials
ABBV Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 134.7 billion | 124.3 billion |
| 2023-09-30 | 136.2 billion | 124.1 billion |
| 2023-06-30 | 135.4 billion | 122.5 billion |
| 2023-03-31 | 134.5 billion | 121.2 billion |
ABBV Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 4.5 billion | 125.0 million |
| 2023-09-30 | 7.4 billion | 130.0 million |
| 2023-06-30 | 6.1 billion | 179.0 million |
| 2023-03-31 | 4.0 billion | 313.0 million |
ABBV Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 826.0 million |
| 2023-09-30 | 1.8 billion |
| 2023-06-30 | 2.0 billion |
| 2023-03-31 | 241.0 million |
ABBV Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 12.8 billion | - | - |
| 2023-09-30 | 13.3 billion | - | - |
| 2023-06-30 | 8.8 billion | 55.8 billion | - |
| 2023-03-31 | 6.7 billion | 59.3 billion | - |
ABBV Shares Outstanding
ABBV Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 205.0 million | 1.9 billion | 3.2 billion | - |
| 2023-09-30 | 219.0 million | 1.7 billion | 3.4 billion | - |
| 2023-06-30 | 178.0 million | 1.7 billion | 3.3 billion | - |
| 2023-03-31 | 175.0 million | 2.3 billion | 3.0 billion | - |
ABBV Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 14.3 billion | 2.4 billion |
| 2023-09-30 | 13.9 billion | 6.5 billion |
| 2023-06-30 | 13.9 billion | 4.2 billion |
| 2023-03-31 | 12.2 billion | 4.0 billion |
ABBV
List: Contenders
Price: $164.66
Dividend Yield: 0.04%
Forward Dividend Yield: 3.77%
Payout Ratio: 227.94%
Dividend Per Share: 6.20 USD
Earnings Per Share: 2.72 USD
P/E Ratio: 63.54
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 6.2 million
Ebitda: 1.9 billionMarket Capitalization: 298.7 billion
Average Dividend Frequency: 4
Years Paying Dividends: 12
DGR3: 7.25%
DGR5: 8.27%
DGR10: 9.99%